THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Doris Benbrook to Biomarkers, Tumor

This is a "connection" page, showing publications Doris Benbrook has written about Biomarkers, Tumor.
Connection Strength

1.279
  1. Similarities and Differences of Hsp70, hsc70, Grp78 and Mortalin as Cancer Biomarkers and Drug Targets. Cells. 2021 11 03; 10(11).
    View in: PubMed
    Score: 0.624
  2. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Nov; 127(2):356-61.
    View in: PubMed
    Score: 0.327
  3. Aberrant NRP-1 expression serves as predicator of metastatic endometrial and lung cancers. Oncotarget. 2016 Feb 16; 7(7):7970-8.
    View in: PubMed
    Score: 0.105
  4. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2007 Sep; 106(3):596-603.
    View in: PubMed
    Score: 0.058
  5. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 May; 105(2):508-16.
    View in: PubMed
    Score: 0.056
  6. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J Natl Cancer Inst. 2001 Apr 04; 93(7):516-25.
    View in: PubMed
    Score: 0.037
  7. A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):291-297.
    View in: PubMed
    Score: 0.028
  8. Immunohistochemical analysis of proliferation and differentiation in organotypic cultures of cervical tumor cell lines. Tissue Cell. 1995 Jun; 27(3):269-74.
    View in: PubMed
    Score: 0.025
  9. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES